Host response to immune checkpoint inhibitors contributes to tumor aggressiveness

BACKGROUND: Immune checkpoint inhibitors (ICIs) have made a paradigm shift in clinical oncology due to unprecedented long-term remissions. However, only a small proportion of patients respond to ICI therapy. It is, therefore, essential to understand the mechanisms driving therapy resistance and to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Khononov, Irina, Jacob, Eyal, Fremder, Ella, Dahan, Nili, Harel, Michal, Raviv, Ziv, Krastev, Boris, Shaked, Yuval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957134/
https://www.ncbi.nlm.nih.gov/pubmed/33707313
http://dx.doi.org/10.1136/jitc-2020-001996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957134/
https://www.ncbi.nlm.nih.gov/pubmed/33707313
http://dx.doi.org/10.1136/jitc-2020-001996

Ejemplares similares